The Serum Lipid Profiles in ITP: a Retrospective Study
The Serum Lipid Profiles in Immune Thrombocytopenia: a Retrospective Study
1 other identifier
observational
457
1 country
1
Brief Summary
The project was retrospectively undertaking by Qilu Hospital of Shandong University in China. In order to investigate the correlations between platelet indices, serum lipids and bleeding symptoms in ITP.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2018
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedFirst Submitted
Initial submission to the registry
September 30, 2021
CompletedFirst Posted
Study publicly available on registry
October 27, 2021
CompletedOctober 27, 2021
October 1, 2021
2.9 years
September 30, 2021
October 14, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Platelet count at 1 month after initial therapy
Platelet count was tested at 1 month after initial therapy
1 month
Interventions
ITP patients were enrolled in this study based on Chinese consensus of ITP.12 Patients were excluded as (1) receiving platelet transfusion within 7 days or ITP-related medication within 3 months (2) treated with lipid-lowing agents, including statins, fibrates, niacin, bile sequestrant resins, ezetimibe and so on.
Eligibility Criteria
A total of 457 ITP patients at Department of Hematology of Qilu Hospital were enrolled in this study based on Chinese consensus of ITP.12 Patients were excluded as (1) receiving platelet transfusion within 7 days or ITP-related medication within 3 months (2) treated with lipid-lowing agents, including statins, fibrates, niacin, bile sequestrant resins, ezetimibe and so on.
You may qualify if:
- Meet the diagnostic criteria for immune thrombocytopenia.
You may not qualify if:
- (1) receiving platelet transfusion within 7 days or ITP-related medication within 3 months (2) treated with lipid-lowing agents, including statins, fibrates, niacin, bile sequestrant resins, ezetimibe and so on.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ming Houlead
Study Sites (1)
Qilu hospital of Shandong university
Jinan, Shandong, 273300, China
Related Publications (1)
Xu P, Han S, Hou M, Zhao Y, Xu M. The serum lipid profiles in immune thrombocytopenia: Mendelian randomization analysis and a retrospective study. Thromb J. 2023 Oct 13;21(1):107. doi: 10.1186/s12959-023-00551-x.
PMID: 37833799DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Manager
Study Record Dates
First Submitted
September 30, 2021
First Posted
October 27, 2021
Study Start
January 1, 2018
Primary Completion
December 1, 2020
Study Completion
December 1, 2020
Last Updated
October 27, 2021
Record last verified: 2021-10